Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have earned an average rating of "Hold" from the twenty-five ratings firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $56.50.

Several research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Sarepta Therapeutics from $50.00 to $25.00 and set a "hold" rating on the stock in a research report on Tuesday, June 17th. Bank of America lowered their target price on shares of Sarepta Therapeutics from $28.00 to $20.00 and set a "neutral" rating on the stock in a report on Friday. Wolfe Research initiated coverage on shares of Sarepta Therapeutics in a research note on Tuesday, June 17th. They issued a "peer perform" rating for the company. Oppenheimer reduced their price objective on shares of Sarepta Therapeutics from $45.00 to $41.00 and set an "outperform" rating for the company in a research note on Friday. Finally, Needham & Company LLC cut shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday.

Sarepta Therapeutics Stock Down 36.0%

Shares of NASDAQ SRPT opened at $14.07 on Friday. Sarepta Therapeutics has a 12-month low of $12.81 and a 12-month high of $150.48. The stock has a market cap of $1.38 billion, a PE ratio of -5.23 and a beta of 0.45. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. The company has a 50-day moving average of $28.42 and a 200 day moving average of $67.97.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The company had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The business's revenue was up 80.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.73 earnings per share. As a group, sell-side analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently bought and sold shares of the stock. New York State Teachers Retirement System grew its stake in shares of Sarepta Therapeutics by 3.3% in the 1st quarter. New York State Teachers Retirement System now owns 79,361 shares of the biotechnology company's stock worth $5,065,000 after purchasing an additional 2,512 shares during the last quarter. Exchange Traded Concepts LLC acquired a new position in shares of Sarepta Therapeutics in the 1st quarter worth approximately $479,000. GAMMA Investing LLC grew its stake in shares of Sarepta Therapeutics by 4,682.8% in the 1st quarter. GAMMA Investing LLC now owns 40,845 shares of the biotechnology company's stock worth $2,607,000 after purchasing an additional 39,991 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Sarepta Therapeutics in the 1st quarter worth approximately $821,000. Finally, PNC Financial Services Group Inc. grew its stake in shares of Sarepta Therapeutics by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock worth $352,000 after purchasing an additional 145 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.